Research progress of CCR5 in nervous system diseases / 中国药理学通报

ABSTRACT

At present, many new discoveries on the pathogenesis of nervous system diseases provide more targets for the research of drugs that treat nervous system diseases. CCR5 is the receptor of CCL3, CCL4 and CCL5, members of the chemokine CC family, and has become an important therapeutic target for nervous system diseases. CCR5 Δ32, as a natural mutation of CCR5, has shown protective effect on a variety of nervous system diseases and has important medical value. The biological role of CCR5 in stroke, Alzheimer' s disease, multiple sclerosis and other neurological diseases has been increasingly studied. Several CCR5 inhibitors have been tested in clinical trials as neuroprotective agents. Therefore, this paper mainly reviews the research progress of CCR5 in the treatment of neurological diseases, in order to provide evidence for the use of CCR5 inhibitors in the treatment of neurological diseases.